Free Trial
NYSE:NUVB

Nuvation Bio (NUVB) Stock Price, News & Analysis

Nuvation Bio logo
$2.80 +0.10 (+3.70%)
(As of 11/22/2024 ET)

About Nuvation Bio Stock (NYSE:NUVB)

Key Stats

Today's Range
$2.66
$2.81
50-Day Range
$2.00
$3.07
52-Week Range
$1.22
$4.16
Volume
3.43 million shs
Average Volume
2.41 million shs
Market Capitalization
$944.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.60
Consensus Rating
Buy

Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
47th Percentile Overall Score

NUVB MarketRank™: 

Nuvation Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 608th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nuvation Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Nuvation Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Nuvation Bio are expected to decrease in the coming year, from ($0.40) to ($0.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nuvation Bio is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nuvation Bio is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nuvation Bio has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nuvation Bio's valuation and earnings.
  • Percentage of Shares Shorted

    4.94% of the float of Nuvation Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvation Bio has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Nuvation Bio has recently increased by 13.54%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nuvation Bio does not currently pay a dividend.

  • Dividend Growth

    Nuvation Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.94% of the float of Nuvation Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvation Bio has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in Nuvation Bio has recently increased by 13.54%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Nuvation Bio has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Nuvation Bio this week, compared to 3 articles on an average week.
  • Search Interest

    Only 6 people have searched for NUVB on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nuvation Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $220,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.07% of the stock of Nuvation Bio is held by insiders.

  • Percentage Held by Institutions

    61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nuvation Bio's insider trading history.
Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

NUVB Stock News Headlines

Nuvation Bio’s Q3 2024 Highlights and Future Prospects
Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
Nuvation Bio (NYSE:NUVB) Stock, Option Chain
See More Headlines

NUVB Stock Analysis - Frequently Asked Questions

Nuvation Bio's stock was trading at $1.51 at the beginning of the year. Since then, NUVB stock has increased by 85.8% and is now trading at $2.8050.
View the best growth stocks for 2024 here
.

Nuvation Bio Inc. (NYSE:NUVB) released its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.02. The business had revenue of $0.73 million for the quarter.

Nuvation Bio's top institutional investors include FMR LLC (11.73%), State Street Corp (1.67%), Geode Capital Management LLC (1.62%) and Charles Schwab Investment Management Inc. (0.56%). Insiders that own company stock include Fund V LP Omega, Oleg Nodelman, Xiangmin Cui and Robert Mashal.
View institutional ownership trends
.

Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvation Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
11/06/2024
Today
11/22/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.60
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+135.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-75,800,000.00
Pretax Margin
-24,619.84%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.49 per share

Miscellaneous

Free Float
319,503,000
Market Cap
$944.08 million
Optionable
Optionable
Beta
1.35
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NYSE:NUVB) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners